Abdel-Moneim A, et al. - In chronic hepatitis C (CHC) genotype (GT) 4 patients in Egypt, researchers examined the efficacy and safety of two regimens sofosbuvir (SOF) in combination with either ribavirin (RBV) or simeprevir (SMV). Based on the type of the regimen used, 201 patients with CHC GT4 infection were allocated into two groups. For this investigation, all eligible patients received oral treatment with SOF plus daily oral weight-based RBV (24 weeks; group 1), or SOF plus daily oral SMV (12 weeks; group 2). The results of this comparative study showed that the combination regimes of SOF/RBV and SOF/SMV are highly effective in the treatment of CHC GT4. The two-direct-acting antiviral agents (DAA) regimen (SOF/SMV) may, however, offer well-tolerated treatment with a shorter duration and better safety than SOF/RBV. Fatigue, headache, nausea, and dyspnea were the most common adverse events in both groups.